Applicants

Yutaka Mizushima et al.

For

DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLE,

PROCESS FOR PRODUCING THE SAME AND PREPARATION

CONTAINING THE MICROPARTICLE

Page

3

In the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Original) Drug-containing sustained release microparticles characterized by comprising a drug other than human growth hormone and a porous apatite derivative.
- 2. (Original) Drug-containing sustained release microparticles characterized by comprising a drug other than human growth hormone, a porous apatite derivative and a water-soluble bivalent metal compound.
- 3. (Currently Amended) The drug-containing sustained release microparticles according to claim 1 of [[2]], characterized in that the porous apatite derivative is a porous apatite derivative in which a portion of calcium as a constituent of hydroxyapatite is substituted with zinc during production.
- 4. (Original) The drug-containing sustained release microparticles according to claim 3, characterized in that the porous apatite derivative has a zinc substitution rate or zinc content rate of 0.1 to 2.0.
- 5. (Original) The drug-containing sustained release microparticles according to claim 2, characterized in that the water-soluble bivalent metal compound is a zinc compound.
- 6. (Original) The drug-containing sustained release microparticles according to claim 5, characterized in that the water-soluble bivalent metal compound is zinc chloride or zinc acetate.

Applicants

Yutaka Mizushima et al.

For

DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLE,

PROCESS FOR PRODUCING THE SAME AND PREPARATION

CONTAINING THE MICROPARTICLE

Page

4

7. (Currently Amended) A preparation for parenteral administration characterized by comprising, drug-containing sustained release microparticles according to any of claims claim 1 to [[6]].

- 8. The preparation according to claim 7, characterized in that the preparation for parenteral administration is either a subcutaneous injection or an intramuscular injection.
- 9. A process for producing drug-containing sustained release microparticles characterized by comprising: dispersing under agitation microparticles of a porous apatite derivative in an aqueous solution containing a drug so that the aqueous solution infiltrates into the porous apatite derivative; adding thereto an aqueous solution containing a water-soluble bivalent metal compound so that the water-soluble bivalent metal compound infiltrates into the porous apatite derivative; further adding an additive such as a stabilizer to the mixture; and effecting lyophilization or vacuum-drying.
- 10. The production process according to claim 9, characterized in that the porous apatite derivative is a porous apatite derivative in which a portion of calcium as a constituent of hydroxyapatite is substituted with zinc during production.
- 11. The production process according to claim 10, characterized in that the porous apatite derivative has a zinc substitution rate or zinc content rate of 0.1 to 2.0
- 12. The process according to claim 9, characterized in that the water-soluble bivalent metal compound is zinc chloride or zinc acetate.